Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells

Annals of Hematology

Volumn 89, Issue 11, 2010, Pages 1081-1087

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute lymphoblastic leukemia; Aurora kinase inhibitor; HDAC inhibitor; T315I mutation

Indexed keywords

ABELSON KINASE; AURORA A KINASE; AURORA B KINASE; BCR ABL PROTEIN; CASPASE 3; CRK LIKE PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE LYN; VORINOSTAT; ANTINEOPLASTIC AGENT; AURORA KINASE; ENZYME INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; TOZASERTIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADULT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG COMBINATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; AURORA KINASES;

EID: 77956956848     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0998-x     Document Type: Article

References (22)

1. CH Pui WE Evans 2006 Treatment of acute lymphoblastic leukemia N Engl J Med 345 166 178 10.1056/NEJMra052603 (Pubitemid 43076714)
2. S Jeha 2009 New therapeutic strategies in acute lymphoblastic leukemia Semin Hematol 46 76 88 1:CAS:528:DC%2BD1MXitVWitLo%3D 10.1053/j.seminhematol. 2008.09.009 19100370
3. CH Pui LL Robison AT Look 2008 Acute lymphoblastic leukaemia Lancet 371 1030 1043 1:CAS:528:DC%2BD1cXjs1SltbY%3D 10.1016/S0140-6736(08)60457-2 18358930 (Pubitemid 351389536)
4. CH Pui S Jeha 2007 New therapeutic strategies for the treatment of acute lymphoblastic leukaemia Nat Rev Drug Discov 6 149 165 1:CAS:528: DC%2BD2sXhtFGlsrs%3D 10.1038/nrd2240 17268486 (Pubitemid 46758753)
5. A Quintás-Cardama H Kantarjian J Cortes 2007 Flying under the radar: the new wave of BCR-ABL inhibitors Nat Rev Drug Discov 6 834 848 10.1038/nrd2324 17853901 (Pubitemid 47500507)
6. H Pfeifer B Wassmann A Pavlova L Wunderle J Oldenburg A Binckebanck T Lange A Hochhaus S Wystub P Brück D Hoelzer OG Ottmann 2007 Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 110 727 734 1:CAS:528:DC%2BD2sXot1emt7c%3D 10.1182/blood-2006-11-052373 17405907 (Pubitemid 47108165)
7. O Gautschi J Heighway PC Mack PR Purnell PN Lara Jr DR Gandara 2008 Aurora kinases as anticancer drug targets Clin Cancer Res 14 1639 1648 1:CAS:528:DC%2BD1cXjtlejtrY%3D 10.1158/1078-0432.CCR-07-2179 18347165 (Pubitemid 351471713)
8. FJ Giles J Cortes D Jones D Bergstrom H Kantarjian SJ Freedman 2007 MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation Blood 109 500 502 1:CAS:528:DC%2BD2sXivVykurc%3D 10.1182/blood-2006-05-025049 16990603 (Pubitemid 46105945)
9. K Ohyashiki J Miyauchi JH Ohyashiki M Saito M Yaguchi Y Inatomi S Nakazawa H Waca S Mizutani Y Matsuo, et al. 1993 Interleukin-7 enhances colony growth and induces CD20 antigen of a Ph+ acute lymphoblastic leukemia cell line, OM9;22 Leukemia 7 1034 1040 1:STN:280:DyaK3szgvFWlsA%3D%3D 7686604
10. S Kimura H Naito H Segawa J Kuroda T Yuasa K Sato A Yokota Y Kamitsuji E Kawata E Ashihara Y Nakaya H Naruoka T Wakayama K Nasu T Asaki T Niwa K Hirabayashi T Maekawa 2005 NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 3948 3954 1:CAS:528:DC%2BD2MXht12ktrzL 10.1182/blood-2005-06-2209 16105974 (Pubitemid 41739036)
11. S Okabe T Tauchi K Ohyashiki 2008 Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells Clin Cancer Res 14 6181 6186 1:CAS:528:DC%2BD1cXhtF2nurjM 10.1158/1078-0432.CCR-08-0461 18829496
12. S Okabe T Tauchi K Ohyashiki HE Broxmeyer 2006 Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45 Blood Cells Mol Dis 36 308 314 1:CAS:528:DC%2BD28XivVGrtrw%3D 10.1016/j.bcmd.2005.12.035 16503409
13. S Okabe S Fukuda YJ Kim M Niki LM Pelus K Ohyashiki PP Pandolfi HE Broxmeyer 2005 Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1 Blood 105 474 480 1:CAS:528:DC%2BD2MXltlGjug%3D%3D 10.1182/blood-2004-03-0843 15345598 (Pubitemid 40070724)
14. WS Xu RB Parmigiani PA Marks PA 2007 Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 5541 5552 1:CAS:528: DC%2BD2sXovFersrY%3D 10.1038/sj.onc.1210620 17694093 (Pubitemid 47255934)
15. U Banerji 2009 Heat shock protein 90 as a drug target: some like it hot Clin Cancer Res 15 9 14 1:CAS:528:DC%2BD1MXhs1Cjug%3D%3D 10.1158/1078-0432.CCR- 08-0132 19118027
16. S Branford Z Rudzki S Walsh A Grigg C Arthur K Taylor R Herrmann KP Lynch TP Hughes 2002 High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 3472 3475 1:CAS:528:DC%2BD38XjtlGqtrk%3D 10.1182/blood.V99.9.3472 11964322 (Pubitemid 34525335)
17. M Deininger E Buchdunger BJ Druker 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640 2653 1:CAS:528:DC%2BD2MXivFGmsb0%3D 10.1182/blood-2004-08-3097 15618470 (Pubitemid 40446252)
18. S Okabe T Tauchi A Nakajima G Sashida A Gotoh HE Broxmeyer JH Ohyashiki K Ohyashiki 2007 Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis Stem Cells Dev 16 503 514 1:CAS:528: DC%2BD2sXnt1Wltr8%3D 10.1089/scd.2007.9994 17610380 (Pubitemid 47016235)
19. S Okabe T Tauchi JH Ohyashiki K Ohyashiki 2009 Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells Biochem Biophys Res Commun 380 775 779 1:CAS:528:DC%2BD1MXis1ejsLg%3D 10.1016/j.bbrc.2009.01.141 19338751
20. D Mahalingam R Swords JS Carew ST Nawrocki K Bhalla FJ Giles 2009 Targeting HSP90 for cancer therapy Br J Cancer 100 1523 1529 1:CAS:528:DC%2BD1MXlslChtrY%3D 10.1038/sj.bjc.6605066 19401686
21. W Fiskus Y Wang R Joshi R Rao Y Yang J Chen R Kolhe R Balusu K Eaton P Lee C Ustun A Jillella CA Buser S Peiper K Bhalla 2008 Concomitant treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells Clin Cancer Res 14 6106 6115 1:CAS:528: DC%2BD1cXhtF2nurvO 10.1158/1078-0432.CCR-08-0721 18829489
22. Y Dai S Chen CA Venditti XY Pei TK Nguyen P Dent S Grant 2008 Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood 112 793 804 1:CAS:528:DC%2BD1cXpsVais78%3D 10.1182/blood-2007-10-116376 18505786